5,816,565Liabilities and Stockholders' Equity (Deficit)Current liabilities:Accounts payable
1,196,861Accrued payroll and related costs512,426440,101Deferred revenue25,00025,000Other accrued expenses, current portion695,965428,497Current portion of long-term debt--419,384Total current liabilities2,452,4282,509,843Other accrued expenses, non-current portion126,911--Long-term debt, net of current portion1,142,4591,589,468Fair value of conversion element of Series B redeemable convertible preference shares of subsidiary82,861194,088Derivative liability for conversion element of convertible promissory notes5,009,088--Warrant derivative liability561,4562,240,962Total liabilities9,375,2036,534,361Series A and B redeemable convertible preference shares of subsidiary3,625,4053,337,476Commitments and contingencies (Note 14)----Stockholders' equity (deficit):Series C convertible preference shares of subsidiary4,993,728--Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,937,499.97 shares issued and outstanding at September 30, 20119,838,569--Common stock, $0.001 par value, 300,000,000 shares authorized, 41,563,180 and 41,175,464 shares issued and outstanding at September 30, 2011, and December 31, 2010 respectively41,56341,175Additional paid-in capital49,090,52038,881,075Accumulated deficit(52,697,855)(43,265,399)Accumulated other comprehensive income23,734287,877Total stockholders' equity (deficit)11,290,259(4,055,272)Total liabilities and stockholders' equity (deficit)
5,816,565Condensed Consolidated Statements of Operations (Unaudited)Three Months Ended September 30,Nine Months Ended September 30,2011201020112010Revenue
|SOURCE WaferGen Biosystems, Inc.|
Copyright©2010 PR Newswire.
All rights reserved